Kelly D Sullivan

List of Publications by Year
in descending order

29	2,147	361413	477307
papers	citations	20 h-index	29 g-index

38	38	38	4078
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy. Neuro-Oncology, 2022, 24, 414-426.	1.2	15
2	Specialized interferon action in COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	56
3	Global Analyses to Identify Direct Transcriptional Targets of p53. Methods in Molecular Biology, 2021, 2267, 19-56.	0.9	3
4	Precocious clonal hematopoiesis in Down syndrome is accompanied by immune dysregulation. Blood Advances, 2021, 5, 1791-1796.	5.2	13
5	Seroconversion stages COVID19 into distinct pathophysiological states. ELife, 2021, 10, .	6.0	40
6	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. Neurology, 2021, 97, 942-957.	1.1	58
7	JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome. Cell Reports, 2020, 33, 108407.	6.4	23
8	Nutlin-Induced Apoptosis Is Specified by a Translation Program Regulated by PCBP2 and DHX30. Cell Reports, 2020, 30, 4355-4369.e6.	6.4	18
9	Multi-Omic Approaches Identify Metabolic and Autophagy Regulators Important in Ovarian Cancer Dissemination. IScience, 2019, 19, 474-491.	4.1	21
10	Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. Nature Communications, 2019, 10, 4766.	12.8	73
11	Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome. Cell Reports, 2019, 29, 1893-1908.e4.	6.4	78
12	Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24231-24241.	7.1	82
13	Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover. Developmental Cell, 2018, 44, 555-565.e3.	7.0	154
14	Mechanisms of transcriptional regulation by p53. Cell Death and Differentiation, 2018, 25, 133-143.	11.2	310
15	Î”Np63Î± Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Reports, 2018, 24, 3224-3236.	6.4	32
16	Trisomy 21 Represses Cilia Formation and Function. Developmental Cell, 2018, 46, 641-650.e6.	7.0	50
17	Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia. Cell, 2017, 168, 59-72.e13.	28.9	99
18	Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity. Genome Research, 2017, 27, 1645-1657.	5.5	123

#	Article	IF	Citations
19	CDK8 Kinase Activity Promotes Glycolysis. Cell Reports, 2017, 21, 1495-1506.	6.4	67
20	Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Scientific Reports, 2017, 7, 14818.	3.3	148
21	Trisomy 21 consistently activates the interferon response. ELife, 2016, 5, .	6.0	238
22	Multivalent Chromatin Engagement and Inter-domain Crosstalk Regulate MORC3 ATPase. Cell Reports, 2016, 16, 3195-3207.	6.4	40
23	Human ACAP2 is a homolog ofC. elegansCNT-1 that promotes apoptosis in cancer cells. Cell Cycle, 2015, 14, 1771-1778.	2.6	8
24	ATM regulates cell fate choice upon p53 activation by modulating mitochondrial turnover and ROS levels. Cell Cycle, 2015, 14, 56-63.	2.6	31
25	A signature for success. ELife, 2015, 4, .	6.0	3
26	Caspase-activated phosphoinositide binding by CNT-1 promotes apoptosis by inhibiting the AKT pathway. Nature Structural and Molecular Biology, 2014, 21, 1082-1090.	8.2	18
27	Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. ELife, 2014, 3, e02200.	6.0	205
28	ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nature Chemical Biology, 2012, 8, 646-654.	8.0	62
29	The p53 circuit board. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 229-244.	7.4	60